Runs clinical trials and provides healthcare data/analytics services that help pharma and biotech companies develop and commercialize drugs.
Runs clinical trials and provides healthcare data/analytics services that help pharma and biotech companies develop and commercialize drugs.
Is paid in two ways: contract fees from drugmakers for running clinical trials, recognised over the life of each study and tracked as backlog, and subscriptions for the data and software descended from IMS Health's prescription-tracking business. It was formed in 2016 by merging Quintiles, a trial-services company, with IMS Health.
Moat: narrow (scale, data, switching costs). Massive proprietary healthcare data assets and a global trial-site network are hard for smaller CROs to match.
Headquarters: Durham, North Carolina, US · Founded: 2016 · Employees: 93,000
Size Iqvia (IQV) is a United States Health Care company (Biotechnology) with a market value of $42.5B, the 286th largest of 3,085 United States companies the cockpit tracks. Shares closed at $257.84 on 18 Nov 2026.
Performance Over six months the shares gained 50.3%, against +25.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 8.9% over the last twelve months (peer median +17.2%); the operating margin is 13.8% (peer median 25.1%).
Valuation It trades at 18.7× forward earnings against a peer median of 25.2× (5th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points below its cost of capital (9.4% WACC).
Backlog Backlog (remaining performance obligations) was $34.2B at 30 Sep 2026, down 1% on a year earlier — 2.0 years of trailing revenue. Backlog detail →
Credit Iqvia has 8 bonds outstanding ($8.14B), rated BB by the agencies and trading like BBB- at a weighted spread of 119 bp.
Short interest Short interest is 1.9% of the free float (30 Oct 2026).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $17.3B | $16.3B | $15.4B | $15.0B | $14.4B |
| Revenue growth | — | +6% | +3% | +4% | — |
| Gross profit | $4.51B | $4.28B | $4.26B | $4.09B | $3.91B |
| EBITDA | $3.62B | $3.42B | $3.38B | $3.17B | $2.97B |
| Net income | $1.39B | $1.36B | $1.37B | $1.36B | $1.09B |
| Free cash flow | $2.08B | $2.05B | $2.11B | $1.50B | $1.59B |
| Capital expenditure | $657M | $603M | $602M | $649M | $674M |
| Total debt | $16.3B | $16.3B | $14.5B | $14.2B | $13.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Iqvia IQV | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% |
| ICON ICLR | $14.6B | +70% | +1% | 10% | 17.3× | 15.9% |
| Labcorp LH | $30.1B | +44% | +6% | 11% | 19.3× | 14.5% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IQV | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.7% | +2.9% | 7th lowest of 19 |
| 6-month return | +50.3% | +25.2% | 5th highest of 19 |
| Distance from 52-week high | -9.4% | -13.3% | 6th highest of 19 |
| Revenue growth (TTM) | +8.9% | +17.2% | 7th lowest of 19 |
| Operating margin | 13.8% | 25.1% | 6th lowest of 19 |
| Forward P/E | 18.7× | 25.2× | 5th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 16.8% | 9.4% | 4th most demanding of 15 |
| Growth delivered (Del g) | +7.5% | +17.1% | 3rd lowest of 15 |
| Hurdle (Req g minus delivered) | +9.3 pp | -8.7 pp | 3rd most demanding of 15 |
| ROIC minus cost of capital | -0.3 pp | +2.2 pp | 9th lowest of 19 |
| EV / EBITDA | 15.6× | 16.4× | 6th cheapest of 15 |
| Net debt / EBITDA | 3.8× | 0.5× | most indebted of 15 |
| Bond spread | 119 bp | 98 bp | widest of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Iqvia IQV | United States | $42.5B | +50% | +9% | 14% | 18.7× | 16.8% | +7.5% |
| Natera NTRA | United States | $42.0B | +41% | +37% | -9% | n/a | n/a | n/a |
| Samsung Biologics 207940.KS | South Korea | $48.7B | -6% | -20% | 43% | 34.4× | 7.0% | +31.4% |
| Celltrion 068270.KS | South Korea | $34.9B | +12% | +40% | 32% | 33.9× | 10.6% | +17.6% |
| Lonza LONN.SW | Switzerland | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% | +7.7% |
| Genmab A/S GMAB.CO | Denmark | $30.8B | +103% | +15% | 31% | 40.9× | 11.6% | +19.5% |
| argenx SE Sponsored ADR ARGX | United States | $59.1B | +17% | +71% | 29% | 29.0× | 11.7% | +151.4% |
| CSL CSL.AX | Australia | $63.7B | +102% | -2% | 26% | 21.5× | 6.8% | +11.0% |
| United Therapeutics UTHR | United States | $24.6B | +2% | +2% | 44% | 23.9× | 0.3% | +16.5% |
| Wuxi Bio 2269.HK | Hong Kong | $23.1B | +35% | +22% | 32% | 26.5× | 20.8% | +30.2% |
| Moderna MRNA | United States | $79.6B | +309% | +13% | -116% | n/a | n/a | n/a |
| BioNTech SE Sponsored ADR BNTX | United States | $20.6B | -8% | -21% | -61% | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | United States | $16.5B | +5% | +38% | 25% | 18.0× | -1.5% | +22.3% |
| BridgeBio Pharma BBIO | United States | $15.2B | +14% | +167% | -37% | n/a | n/a | n/a |
| Elanco Animal Health ELAN | United States | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% | +7.6% |
| Cspc Pharma 1093.HK | Hong Kong | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% | +0.1% |
| BioMarin Pharmaceutical BMRN | United States | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% | +12.0% |
| Bio-Techne TECH | United States | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% | +5.5% |
| Halozyme Therapeutics HALO | United States | $10.9B | +39% | +45% | 57% | 9.5× | -0.3% | +39.2% |
Iqvia has 8 bonds outstanding with $8.14B face value. The agencies rate it BB; its bonds trade like BBB-. Weighted yield 5.09%, a spread of 119 bp over government bonds.
Iqvia reported $34.2B of remaining performance obligations at 30 Sep 2026, down 1% from a year earlier and down 6% from the previous quarter. That is 2.0 years of trailing revenue already under contract. Book-to-bill last quarter: 0.50.